



For Immediate Release

April 11, 2024

Acuitas Therapeutics Named One of Canada's Top Small & Medium Employers

Vancouver, B.C. – On top of the recent naming of Acuitas Therapeutics, Inc. as one of [BC's Top Employers of 2024](#), the organization was just named one of [Canada's Top Small & Medium Employers of 2024](#). The Vancouver-based, privately held biotechnology firm is the global leader in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles.

“We are honoured to be named as one of Canada's Top Small & Medium Employers,” said President & CEO Dr. Thomas Madden. He added: “We have some of the world's best scientists and business professionals on our team, and we are dedicated to the transformative power of science – in our case, biotechnology – to improve lives. Our scientific innovation attracts exceptional talent, and our culture of innovation and collaboration retains them. It is a great combination. From the moment when we opened Acuitas, a priority has been to develop and maintain a positive company culture and everyone on the team is committed to this. We have a culture where everyone feels respected, heard and valued – and where we have fun together. This, to me, is an exceptional achievement and credit belongs to the entire Acuitas team.”

About Acuitas Therapeutics

Vancouver-based Acuitas Therapeutics (www.acuitastx.com) partners with pharmaceutical and biotechnology companies, as well as non-governmental organizations and academic institutes, to advance nucleic acid therapeutics into clinical development and commercialization. Acuitas' lipid nanoparticle (LNP) technology is clinically validated, enabling Alnylam Pharmaceuticals' ONPATTRO® for the treatment of people with a rare genetic and otherwise fatal disorder known as transthyretin amyloidosis and the Pfizer-BioNTech COVID-19 vaccine, COMIRNATY®, which has protected billions of people in more than 180 countries. Acuitas has also helped to enable the first human proof-of-concept for genome base editing to treat a serious genetic disease. The company is currently focused on further innovations to its LNP carriers to advance the development of novel gene therapies, such as epigenetic medicines, to modulate gene expression without genetic editing to treat a range of diseases, including cancer. In addition, Acuitas works with partners on the development of improved vaccines – such as multi-valent vaccines to prevent a range of infectious diseases (including malaria, HIV/AIDS and tuberculosis) – and on novel therapeutic vaccines against cancer, including personalized cancer vaccines.

-END-